Kodiak Sciences stock gets closer to a BLA after DAYBREAK data
Kodiak Sciences' stock is moving closer to a Biologics License Application (BLA) following positive Phase 3 DAYBREAK study data for Zenkuda and tabirafusp-ted in wet age-related macular degeneration. Zenkuda demonstrated non-inferior vision gains and extended dosing intervals, while tabirafusp-ted met vision and anatomical endpoints with favorable safety profiles. The company plans to submit a multi-indication BLA in Q4 2026, despite a Q2 net loss, and analysts show a "Strong Buy" consensus with an average price target significantly above the current stock price.
Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?
Kodiak Sciences (KOD), Repligen (RGEN), and Biogen (BIIB) stocks all reached 52-week highs due to positive company news. Kodiak Sciences surged after its experimental drugs met primary endpoints in a Phase 3 trial. Repligen saw gains following strong Q2 2026 earnings, increased financial guidance, and an expansion into cell therapy. Biogen's rise was attributed to robust Q2 2026 earnings, strategic acquisitions, and positive updates to its product pipeline.
Kodiak Sciences’ Two Wet AMD Treatments Match Aflibercept in Phase III Study
Kodiak Sciences reported that its Phase III DAYBREAK study demonstrated that two investigational treatments for wet age-related macular degeneration (wet AMD), Zenkuda (tarcocimab) and tabirafusp-ted (KSI-501), met primary endpoints by showing statistical equivalence to aflibercept in visual acuity outcomes. The company plans to submit a multi-indication biologics license application for Zenkuda this year, covering wet AMD, diabetic retinopathy, and retinal vein occlusion. Kodiak is also continuing the development of tabirafusp-ted and KSI-101.
Kodiak Sciences’ Two Wet AMD Treatments Match Aflibercept in Phase III Study
Kodiak Sciences announced that two of its investigational treatments for wet age-related macular degeneration (wet AMD), Zenkuda and tabirafusp-ted, met their primary endpoints in Phase III studies, demonstrating non-inferiority and equivalence to aflibercept. Zenkuda showed potential for extended dosing, with 54% of patients reaching a six-month interval, and Kodiak plans a multi-indication biologics license application for it this year. The company is also advancing other retinal disease programs and aims to transition to a commercial-stage company.
Show Me The Money: Kodiak Sciences Shares Deliver More Than 500% Return In Just Over A Year
Kodiak Sciences Inc. (KOD) has seen remarkable stock performance, with shares nearly tripling in a month and delivering over 500% returns in just over a year. The biopharmaceutical company, specializing in ophthalmic diseases, has been driven by positive clinical trial results for its pipeline drugs Zenkuda, Tabirafusp tedromer, and KSI-101. Upcoming catalysts, including topline data releases and planned Biologics License Application submissions, are expected to continue influencing the stock's trajectory.
Learn Why The Bull Case For Kodiak Sciences Stock Could Change Following Late Stage Eye Disease Trial Win
Kodiak Sciences (NasdaqGM:KOD) has reported positive results from its Phase 3 DAYBREAK trial for Zenkuda and tabirafusp-ted in wet age-related macular degeneration, meeting primary endpoints with non-inferior vision gains and favorable safety. The company plans to submit a three-indication BLA for Zenkuda, shifting its investment narrative from scientific risk to execution in a competitive market. Despite the clinical success, Kodiak Sciences remains pre-revenue and loss-making, raising questions about funding, dilution, and share price volatility.
In 30 transactions, Baker funds bought shares of Kodiak Sciences (KOD).
Baker funds, specifically 667, L.P. and Baker Brothers Life Sciences, L.P., purchased a total of 807,840 common shares of Kodiak Sciences Inc. (KOD) on September 28, 2026, across 30 transactions. The shares were bought at weighted-average prices ranging from $61.2104 to $78.5681 per share. The transactions did not involve a Rule 10b5-1 plan.
Kodiak Sciences Soars 141% on “Truly Impressive” Pivotal Wet AMD Trial Win
Kodiak Sciences' shares surged 141% after its drug Zenkuda successfully met its primary endpoint in the pivotal Phase 3 DAYBREAK trial for wet AMD. Zenkuda demonstrated comparable vision gains to aflibercept, with over half of patients on a 6-month dosing schedule, highlighting its significant durability. The company plans to seek FDA approval in Q4 2026, supported by five positive Phase 3 studies, and will likely pursue a cash raise to fund its commercial launch.
MongoDB, Kodiak Sciences, Navitas Semiconductor, Boeing and Nvidia: Why These 5 Stocks Are on Investors' Radars Today
Major U.S. indices closed lower on Monday, influenced by rising U.S. Treasury yields and oil prices. This article highlights five stocks—MongoDB, Kodiak Sciences, Navitas Semiconductor, Boeing, and Nvidia—that garnered significant investor attention. Their movements were driven by factors like CEO departures, positive clinical trial results, strategic government contracts, software glitches, and substantial share buyback authorizations.
Kodiak Sciences (KOD) Rockets As Phase 3 Catalysts Loom
Kodiak Sciences (KOD) stock surged by 176.45% following positive trial data for its eye drug, tarcocimab, and as pivotal Phase 3 DAYBREAK results for Zenkuda and KSI-501 in wet AMD are presented. UBS reiterated a "Buy" rating with an $80 target, while Goldman Sachs issued a "Neutral" rating with a $36 target, highlighting differing analyst views on the company's future. The stock's volatile movement reflects its status as a data-driven trade, with its valuation heavily reliant on the upcoming clinical trial outcomes.
Kodiak Sciences (KOD) Climbs Nearly 3x on Promising Wet AMD Trial
Kodiak Sciences (KOD) saw its stock price nearly triple to a five-year high after its wet AMD treatment candidate, Zenkuda, showed promising phase 3 trial results, demonstrating non-inferiority to aflibercept with the potential for fewer injections. Despite the positive news, Jefferies reduced its price target for KOD but maintained a buy recommendation, while second-quarter hedge fund sentiment showed a dip in committed capital, although pre-dating the trial results. Investors are now awaiting a biologics license application (BLA) from Kodiak Sciences in the fourth quarter.
Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial
Kodiak Sciences (NASDAQ:KOD) saw its stock surge over 162% after its experimental drugs, Zenkuda and tabirafusp-ted, met their primary endpoints in the phase III DAYBREAK trial for wet age-related macular degeneration. Both drugs demonstrated noninferiority to aflibercept in vision gains at one year and exhibited a safety profile consistent with aflibercept. Kodiak plans to submit Zenkuda's biologics license application in Q4 2026 for approval across wet AMD, diabetic retinopathy, and macular edema.
Kodiak Sciences posts positive Phase 3 DAYBREAK eye results
Kodiak Sciences reported positive Phase 3 DAYBREAK trial results for its wet age-related macular degeneration drugs, Zenkuda and tabirafusp-ted, both meeting primary endpoints with vision gains non-inferior to aflibercept. Zenkuda demonstrated strong durability with 54% of patients on six-month dosing and is set for U.S. approval filing in Q4 2026. These results validate Kodiak's ABC platform and its strategy to develop long-acting ocular therapies for retinal diseases.
Kodiak Sciences: Zenkuda and tabirafusp-ted meet primary endpoints in Phase 3 DAYBREAK
Kodiak Sciences announced that its drugs, Zenkuda and tabirafusp-ted, successfully met primary endpoints in the Phase 3 DAYBREAK trial for wet Age-related Macular Degeneration (AMD). Zenkuda demonstrated meaningful vision gains and sustained retinal drying, with 54% of patients achieving 6-month dosing, while tabirafusp-ted also met its vision primary endpoint and anatomical key secondary endpoints. Kodiak plans a multi-indication Biologics License Application (BLA) submission for Zenkuda in Q4 2026, based on five positive Phase 3 studies.
Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial
Kodiak Sciences' shares surged over 162% after its experimental drugs Zenkuda and tabirafusp-ted met primary endpoints in the phase III DAYBREAK trial for wet age-related macular degeneration. Both drugs demonstrated noninferiority to aflibercept in vision gains at one year and exhibited a safety profile consistent with aflibercept. Kodiak plans to submit Zenkuda's biologics license application in Q4 2026, seeking approval for wet AMD, diabetic retinopathy, and macular edema.
Kodiak Sciences skyrockets as Zenkuda, tabirafusp excel in late-stage wet AMD trial
Kodiak Sciences saw its stock surge by approximately 145% after announcing positive results from a late-stage clinical trial for its wet age-related macular degeneration (wet AMD) treatments. Both Zenkuda (tarcocimab tedromer) and tabirafusp alfa tedromer (KSI-501) met key goals in the DAYBREAK study, indicating promising efficacy for the company's therapeutic candidates.
In a vision trial, 54% of patients went six months between eye treatments
Kodiak Sciences' Zenkuda and tabirafusp-ted met primary vision endpoints in the Phase 3 DAYBREAK trial for wet age-related macular degeneration (wAMD). Zenkuda achieved non-inferior vision gains compared to aflibercept, with 54% of patients maintaining a six-month dosing interval at year one under strict treat-to-dryness criteria. Kodiak plans a multi-indication Biologics License Application (BLA) for Zenkuda in Q4 2026, encompassing wAMD, diabetic retinopathy, and retinal vein occlusion.
Kodiak Sciences to Report DAYBREAK Phase 3 Results for Zenkuda and KSI-501
Kodiak Sciences is set to release topline results from its DAYBREAK Phase 3 study on September 28th, evaluating Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) against aflibercept for wet age-related macular degeneration. The study's "unusual design" allows for simultaneous assessment of two distinct agents. The primary endpoint will be visual acuity change from baseline relative to aflibercept, determining if either drug meets the non-inferiority threshold in a competitive anti-VEGF market.
Kodiak Sciences to reveal Phase 3 DAYBREAK study results for wet AMD treatments on Sept 28
Kodiak Sciences is scheduled to release the topline results from its Phase 3 DAYBREAK study on September 28, 2026. This study evaluates Zenkuda™ and KSI-501 for the treatment of wet age-related macular degeneration (AMD), targeting a significant $15 billion market. The announcement will be available via a webcast for investors and interested parties.
Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration
Kodiak Sciences (Nasdaq: KOD) announced it will report topline results from its DAYBREAK Phase 3 study on September 28, 2026. This study evaluates Zenkuda™ (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) for treating wet age-related macular degeneration. The company, a precommercial retina-focused biotechnology firm, is also developing other late-stage clinical programs for various retinal diseases.
Kodiak Sciences to report phase 3 trial results Monday By Investing.com
Kodiak Sciences Inc. (NASDAQ:KOD) is set to release topline results from its DAYBREAK Phase 3 study on Monday, September 28. This study evaluates Zenkuda and KSI-501 for treating wet age-related macular degeneration. The biotechnology company will host a webcast at 8:30 AM Eastern Time to present these findings.
Results are due Monday from a study of two potential treatments for an age-related eye disease.
Kodiak Sciences (KOD) is set to report topline results from its DAYBREAK Phase 3 study on September 28, 2026. This study evaluates Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) for treating wet age-related macular degeneration. The company will host a webcast to discuss the findings, which are highly anticipated due to their potential impact on the anti-VEGF market.
What DAYBREAK Trial Results Could Mean For Kodiak Sciences Stock
Kodiak Sciences is nearing the release of top-line results from its phase III DAYBREAK trial for Zenkuda and KSI-501, targeting wet age-related macular degeneration. The outcome of this trial is critical for the company, given its focus on a single retinal platform, current lack of significant revenue, and limited cash runway. The results will heavily influence investor perception of its potential in the multi-billion dollar anti-VEGF market and the credibility of its entire retinal vascular pipeline.
Goldman Sachs initiates Kodiak Sciences stock coverage with neutral rating By Investing.com
Goldman Sachs has initiated coverage on Kodiak Sciences Inc. (NASDAQ:KOD) with a Neutral rating and a $36.00 price target. Despite a 103% return over the past year, the stock is considered overvalued with high volatility. Kodiak Sciences, a clinical-stage biotech company, is advancing several ophthalmic therapies, including Zenkuda, which is supported by successful Phase 3 trials.
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte
This Zacks Analyst Blog highlights four biotech stocks—Kodiak Sciences (KOD), Celldex Therapeutics (CLDX), Rapport Therapeutics (RAPP), and Vaxcyte (PCVX)—that are poised for significant clinical readouts this fall. These readouts, spanning various therapeutic areas, are crucial catalysts for these companies, with potential to materially shift investor expectations and stock prices based on study results. The article details the specific late-stage studies and anticipated data releases for each company, emphasizing their potential impact on future regulatory and commercial prospects.
Kodiak Sciences stock faces a clinical catalyst this fall
Kodiak Sciences (KOD) stock is facing a critical clinical catalyst this fall, with a clinical readout expected for a biotechnology trial. The stock currently holds a Zacks Rank 4 Sell, making the upcoming trial data the central event influencing its valuation. Investors are watching to see if the clinical results will confirm or challenge the market's current expectations, as the company's risk remains tied to this event-driven biotechnology position.
4 Biotech Stocks With Key Clinical Readouts Expected This Fall
This article highlights four biotech stocks – Kodiak Sciences (KOD), Celldex Therapeutics (CLDX), Rapport Therapeutics (RAPP), and Vaxcyte (PCVX) – that have significant clinical readouts anticipated in the fall, which could dramatically impact their valuations. These readouts cover various therapeutic areas including ophthalmology, immunology, neuroscience, and vaccines. The companies' future prospects hinge on these study results, making them key watch targets for investors.
Kodiak Sciences (KOD) Pulls Back After A Strong Year, Is The Valuation Still Too Rich?
Kodiak Sciences (KOD) has experienced a recent pullback in its share price after a strong year, raising questions about its current valuation. While its price-to-book ratio of 33.6x appears high compared to the broader biotech industry, it's lower than its closest peers, and a discounted cash flow (DCF) model suggests the stock is trading significantly below its estimated fair value of $374.58. Investors are advised to consider the underlying assumptions of these valuation models and the company's risks, including its current losses and clinical trial outcomes.
H.C. Wainwright reiterates Kodiak Sciences stock rating on trial outlook By Investing.com
H.C. Wainwright has reiterated a Buy rating and a $58 price target for Kodiak Sciences (NASDAQ:KOD) due to the promising outlook of its Phase 3 DAYBREAK and PEAK trials. The DAYBREAK trial's one-year primary endpoint topline for wet AMD patients is expected in September 2026, while the PEAK pivotal analysis for Macular Edema Secondary to Inflammation is anticipated in December 2026. Despite a recent financial loss, the firm maintains confidence in Kodiak Sciences' retinal therapeutics pipeline and upcoming clinical readouts.
Kodiak Sciences: DAYBREAK Needs To Deliver More Than A Passing Grade (NASDAQ:KOD)
Kodiak Sciences is awaiting Phase 3 DAYBREAK results for its treatments Zenkuda and KSI-501 for wet AMD this month. While the company has a chance to introduce a longer-lasting treatment, the key challenge is whether the clinical results will provide enough compelling reasons for physicians to adopt them, especially considering the current $2.1 billion valuation which already anticipates positive outcomes. The author rates KOD as a Hold, noting that a routine positive headline may not justify the current valuation given the need for significant advancements in patient vision and dosing intervals to truly succeed.
Vitreoretinal Disorder Market Analysis Highlights Growth To $6.71 Billion By 2030 At 7.7% CAGR
The vitreoretinal disorder market is projected to reach $6.71 billion by 2030, growing at a 7.7% CAGR, driven by advancements in treatment and diagnostics, personalized care, and innovative technologies. Key trends include advanced retinal imaging, minimally invasive surgeries, AI diagnostics, and targeted therapies. Merck's acquisition of Eyebiotech Limited for $3 billion highlights the industry's focus on expanding eye disease treatment portfolios.
What Kodiak Sciences (KOD)'s Widening Net Losses and Lower H1 Loss Per Share Mean For Shareholders
Kodiak Sciences Inc. reported a widening net loss in Q2 2026 and for the first half of 2026, though its basic loss per share for H1 improved. The company, a pre-revenue biopharmaceutical firm, continues to rely on the success of its eye disease pipeline, particularly KSI-101 and Zenkuda, to offset its significant cash burn. Investors are closely watching trial milestones and the company's limited cash runway, which suggests a potential need for fresh capital.
HC Wainwright Lowers Earnings Estimates for Kodiak Sciences
HC Wainwright has revised its Q3 2026 earnings per share (EPS) estimates for Kodiak Sciences, lowering it to a loss of $0.89 from $0.80, while maintaining a "Buy" rating and a $58 price target. This adjustment follows Kodiak Sciences reporting a Q2 loss of $1.05 per share, which missed the consensus estimate. Despite the lowered estimates, the overall analyst consensus for Kodiak Sciences remains a "Moderate Buy" with an average target price of $48.14.
GSA Capital Partners LLP Takes $1.07 Million Position in Kodiak Sciences Inc. $KOD
GSA Capital Partners LLP acquired a new position in Kodiak Sciences Inc. (NASDAQ:KOD) during the second quarter, purchasing 27,525 shares valued at approximately $1.07 million. Institutional investors and hedge funds now own 89.06% of Kodiak Sciences stock. Analyst sentiment for the company is a "Moderate Buy" with an average price target of $48.14, despite missing recent quarterly earnings estimates.
H.C. Wainwright Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $58
H.C. Wainwright has reiterated its Buy rating on Kodiak Sciences (KOD.US) and maintained a target price of $58. This indicates the firm's continued confidence in the company's prospects. Investors may find this analyst rating useful in their evaluation of Kodiak Sciences.
KOD Reiterates by HC Wainwright & Co. -- Price Target Maintained at $58
HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating for Kodiak Sciences (KOD), maintaining a price target of $58.00 despite the company's current stock price of $41.37. The company, which operates in the biotechnology sector and focuses on retinal medicines, has a low GF Score™ of 27/100, indicating areas for improvement in profitability and growth. Insider activity shows $1.0 million in selling over the last three months with no buying, and guru ownership is mixed.
HC Wainwright Reaffirms "Buy" Rating for Kodiak Sciences (NASDAQ:KOD)
HC Wainwright has reiterated its "Buy" rating for Kodiak Sciences (NASDAQ:KOD) and set a $58 price target, indicating a potential upside of approximately 40%. Despite a quarterly loss of $1.05 per share, below analyst estimates, the company maintains a "Moderate Buy" consensus rating from analysts. Institutional investors hold a significant 89.06% stake in the clinical-stage biopharmaceutical company, which focuses on developing therapies for retinal diseases.
H.C. Wainwright reiterates Kodiak Sciences stock rating at buy
H.C. Wainwright has reiterated a buy rating and a $58.00 price target for Kodiak Sciences Inc. (NASDAQ:KOD), highlighting the stock's significant surge over the past year. The firm anticipates key topline data from two Phase 3 trials in September and December 2026, which are considered near-term catalysts for the company's retinal therapeutics pipeline. Despite these potential advancements, Kodiak Sciences reported a wider-than-expected net loss in its Q2 financial results, primarily due to increased research and development expenses.
H.C. Wainwright reiterates Kodiak Sciences stock rating at buy
H.C. Wainwright has reiterated a buy rating and a $58.00 price target for Kodiak Sciences Inc. (NASDAQ: KOD), whose stock has seen a 291% surge over the past year. The firm highlighted two near-term catalysts in the company's retinal therapeutics pipeline: the Phase 3 DAYBREAK trial's primary endpoint topline in September 2026 and the Phase 3 PEAK pivotal analysis-1 topline in December 2026. Despite a wider net loss reported in the second quarter, these advancements underscore the company's ongoing efforts in its late-stage clinical programs.
California State Teachers Retirement System Has $1.12 Million Stock Holdings in Kodiak Sciences Inc. $KOD
The California State Teachers Retirement System significantly increased its stake in Kodiak Sciences Inc. (NASDAQ:KOD) by 1,358.9% in the first quarter, now holding 29,396 shares valued at $1.12 million. Other institutional investors also adjusted their positions, with 89.06% of the stock owned by institutional investors and hedge funds. Despite missing analyst earnings expectations, Kodiak Sciences maintains a "Moderate Buy" consensus rating with a price target of $48.14.
Wall Street Zen Downgrades Kodiak Sciences (NASDAQ:KOD) to Sell
Wall Street Zen downgraded Kodiak Sciences (NASDAQ:KOD) from "hold" to "sell" on Saturday, despite the broader analyst consensus being a "Moderate Buy." The company's shares opened near their 52-week high at $41.35, but Kodiak Sciences reported a larger-than-expected quarterly loss of $1.05 per share. Institutional investors hold a significant portion of the company's stock, with major investments from firms like BlackRock Inc. and Baker Bros. Advisors.
UBS Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $80
UBS has reiterated its Buy rating for Kodiak Sciences (KOD.US) and maintained its target price at $80. This indicates a continued positive outlook from the financial institution regarding the company's stock performance.
Kodiak Sciences misses Q2 estimates, shares fall 5% By Investing.com
Kodiak Sciences Inc. reported a wider Q2 net loss of -$1.05 per share, missing analyst estimates of -$0.98 per share, leading to a 5.23% drop in shares. The biotechnology company's research and development expenses increased due to heightened clinical activities for its retinal disease programs. Despite the Q2 miss, Kodiak expects its cash reserves to support operations into 2027 and anticipates key Phase 3 clinical trial results later this year.
Kodiak Sciences (NASDAQ:KOD) Shares Gap Down - Time to Sell?
Kodiak Sciences (NASDAQ:KOD) shares gapped down before Friday's market open, though they later recovered some ground. The clinical-stage biopharmaceutical company, which focuses on retinal disease treatments, reported a quarterly loss that missed analyst estimates. Despite the earnings miss, analyst sentiment is generally positive, with a "Moderate Buy" consensus rating and an average price target above the current trading price.
Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus
Kodiak Sciences reported a wider-than-expected Q2 2026 loss of $1.05 per share, surpassing the Zacks Consensus Estimate of a 97-cent loss. Despite increased R&D expenses for pipeline development, the company's cash position is expected to sustain operations into 2027. Kodiak is accelerating regulatory submissions for its lead candidate Zenkuda and advancing other investigational therapies, KSI-501 and KSI-101, for various retinal diseases.
Kodiak Sciences misses Q2 estimates, shares fall 5%
Kodiak Sciences Inc. (NASDAQ:KOD) reported a wider net loss of -$1.05 per share for Q2, missing analyst estimates of -$0.98 per share, leading to a 5.23% drop in shares after hours. The biotechnology company's R&D expenses increased due to clinical activities for its retinal disease programs, but it expects its current cash to fund operations into 2027. The company is anticipating key Phase 3 clinical trial results in September and December 2026.
Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus
Kodiak Sciences (KOD) reported a wider-than-expected Q2 2026 loss of $1.05 per share, primarily due to increased R&D expenses for ongoing clinical studies. Despite this, the company's shares have risen significantly year-to-date, driven by advancements in its pipeline, including the accelerated regulatory submission for its lead candidate, Zenkuda, and progress in studies for KSI-501 and KSI-101 for retinal vascular diseases. Kodiak expects its cash position to fund operations into 2027.
Kodiak Sciences (NASDAQ:KOD) Releases Earnings Results, Misses Estimates By $0.09 EPS
Kodiak Sciences (NASDAQ:KOD) reported a quarterly loss of $1.05 per share, missing analysts' consensus estimates by $0.09. Following the earnings release, the stock fell 7.9% to $39.98, despite a "Moderate Buy" consensus rating and an average price target of $48.14 from analysts. Institutional investors own a significant portion of the company's stock, with several firms adjusting their positions recently.
Kodiak Sciences misses Q2 estimates, shares fall 5%
Kodiak Sciences Inc. reported a wider net loss of -$1.05 per share in Q2, missing analyst estimates of -$0.98 per share, causing shares to drop over 5% in after-hours trading. The company's R&D expenses increased due to late-stage clinical programs for retinal diseases, though it expects current cash to fund operations into 2027 with several Phase 3 readouts anticipated by year-end.
Kodiak Sciences posts Q2 2026 net loss of $65.6M, cash $125.9M; DAYBREAK, PEAK readouts due Sept–Dec 2026
Kodiak Sciences reported a Q2 2026 net loss of $65.6 million and ended the quarter with $125.9 million in cash, expected to fund operations into 2027. The company reiterated upcoming Phase 3 topline readouts for DAYBREAK in September 2026 and PEAK Pivotal Analysis 1 in December 2026. Research and development expenses increased to $56.1 million due to higher Phase 3 clinical and manufacturing activities.
